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Abstract
Background: Cardiovascular disease (CVD) is the leading cause of death in the developed world. Human genetic
studies, including genome-wide sequencing and SNP-array approaches, promise to reveal disease genes and
mechanisms representing new therapeutic targets. In practice, however, identification of the actual genes contributing
to disease pathogenesis has lagged behind identification of associated loci, thus limiting the clinical benefits.
Results: To aid in localizing causal genes, we develop a machine learning approach, Objective Prioritization for
Enhanced Novelty (OPEN), which quantitatively prioritizes gene-disease associations based on a diverse group of
genomic features. This approach uses only unbiased predictive features and thus is not hampered by a preference
towards previously well-characterized genes. We demonstrate success in identifying genetic determinants for
CVD-related traits, including cholesterol levels, blood pressure, and conduction system and cardiomyopathy
phenotypes. Using OPEN, we prioritize genes, including FLNC, for association with increased left ventricular
diameter, which is a defining feature of a prevalent cardiovascular disorder, dilated cardiomyopathy or DCM. Using
a zebrafish model, we experimentally validate FLNC and identify a novel FLNC splice-site mutation in a patient with
severe DCM.
Conclusion: Our approach stands to assist interpretation of large-scale genetic studies without compromising
their fundamentally unbiased nature.
Background
Genetic variant discovery offers two potential clinical ben-
efits: improved estimation of disease risk for individual
patients, and identification of novel therapeutic targets [1].
Although the predictive utility of common disease variants
has been modest, unexpected connections between genes
and diseases, such as the role of the complement pathway
in age-related macular degeneration [2], have emerged to
steer treatment strategies in promising, unforeseen direc-
tions [3].
Genetic studies can contribute to target discovery only
if the genes underlying the genotype-phenotype relation-
ship can be identified unambiguously. In the case of
genome-wide association (GWA) studies, the associated
single nucleotide polymorphism (SNP) is typically only a
proxy for a ?block? of variants with closely correlated
genotypes, so that the associated SNP is often termed a
?tag SNP? . The associated blocks can be separated by
many tens of kilobases (kb), and can overlap dozens of
genes [4], any one of which might harbor the causal
variant. The interpretation of sequencing-based studies
of human disease has also been challenging: the thou-
sands of potentially deleterious mutations in the human
genome have made it difficult to pinpoint the actual
causal gene(s) [5].
To resolve this ambiguity, investigators have turned to
'pathway' approaches, where increased confidence in the
causality of genes is derived from genes at multiple loci
sharing some functional aspects [6]. Although such ap-
proaches have helped identify some commonality amongst
genes at implicated loci, such as the importance of the
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rely in whole or in part on biased, investigator-driven gene
annotation - for example, Gene Ontology (GO) terms
[8-11], protein-protein interactions from studies targeting
specific proteins of interest [12,13], or published abstract
co-occurrence [14]. This presents a paradox - despite
starting from unbiased genome-wide data, such pathway
approaches tend to identify only well-studied genes.
Genetic research in cardiovascular disease (CVD) has
fit the general pattern described above. Our understanding
of both Mendelian and complex forms of CVD has bene-
fited from the application of genome-wide technologies,
with hundreds of loci implicated in such important disease
traits as cholesterol and triglyceride level [15], cardiac
conduction phenotypes [16-20], and disorders of cardiac
muscle [21,22]. Nonetheless, progression from this vast
catalog of data towards actual therapeutic targets has been
hampered by the inability to separate causal genes from
bystanders.
As an aid to interpreting large-scale association and
sequencing data in CVD, we have developed a strategy
we term Objective Prioritization for Enhanced Novelty
(OPEN), a machine learning approach that prioritizes
causal genes based entirely on the sharing of unbiased
genomic features. Our approach uses either GWA loci
or Mendelian disease genes as a source of positive train-
ing examples, and derives a predictive model that can be
applied to score all genes in the genome for likelihood of
disease association. Using publicly available databases,
we compiled >40,000 genomic features capturing diverse
gene characteristics, none of which would be expected
to favor well-studied genes. We assessed our method on
a variety of cardiac traits using cross-validation and ob-
served strong performance. Furthermore, with the help
of OPEN-prioritized gene-disease associations from a
GWA study on left ventricular dimension, we identified
promising candidate causal genes that would otherwise
have failed genome-wide significance criteria. Three of
these genes (SVIL, FLNC, USP13) were validated in a
zebrafish model of cardiac function. Finally, we se-
quenced the exons of these prioritized candidates in
patients with idiopathic dilated cardiomyopathy (DCM),
and found one patient harboring a conserved splice-
site mutation in the novel cardiomyopathy-associated
FLNC gene.
Results
Here we describe 1) an overview of the OPEN approach,
2) assembly of unbiased genomic features we used, 3) the
objective use of prior experimental data to weight training
examples, 4) details of the OPEN algorithm, and 5) an
evaluation of performance, through cross-validation, expe-
rimental follow-up, and genetic sequencing of novel
candidate genes in patients affected with CVD.
The OPEN strategy for prediction of causal genes
To perform OPEN, we start with a list of genomic loci
associated with a disease of interest, each represented by
a single tag SNP (Figure 1), or, in the case of Mendelian
disease, a list of genes previously implicated by linkage
or whole exome analysis. For GWA, we initially map
each tag SNP to neighboring genes in two steps. First,
we identify an associated ?block? of SNPs in linkage dis-
equilibrium with the tag SNP (using a threshold r
2 value
of 0.5). Second, we identify all genes overlapping this
block (Figure 1A; Materials and methods). To account
for the fact that enhancers may act at a great distance,
we define genes by an inclusive interval extending 250
kbp to either side of a transcription start site. SNPs that
reside within the gene body, as defined by transcription
start and stop sites, are also assigned to the correspond-
ing gene. Additional SNPs are included on the basis of
linkage disequilibrium and nucleotide distance. For each
phenotype we identify loci containing tagSNPs, and the
gene(s) overlapping these loci represent our initial positive
training examples. At each locus, we then apply a weight
to each gene that reflects proximity to the tag SNP as well
as prior experimental evidence that implicates it in a rele-
vant biological process. Such evidence might include asso-
ciation with a Mendelian form of the disease, an ortholog
in a mouse model that exhibits a cognate phenotype, or
annotation with a GO term that is held by other genes
associated with the disease of interest. We then apply two
rounds of machine learning. The purpose of the first
round is to limit and refine the list of training examples
from among genes at disease-associated loci, while the
second round aims to score candidate genes according to
likelihood of disease association. The output of the first
round is a reduced subset of positive training examples
that stand out relative to their peers at each locus (see
Materials and methods). Genes are not selected from loci
which contain many genes unless they are high-scoring
outliers, while genes at sparse loci (loci containing a small
number of genes within the linkage disequilibrium win-
dow) have a high likelihood of being included. The second
round uses this enriched set of positive examples for train-
ing to derive a predictive model of disease association. For
predictions related to Mendelian disease association,
where there is no ambiguity in SNP-to-gene mapping,
the first round is skipped, and all training examples
are retained for the second round.
Note that, like all other disease gene prioritization
strategies, our positive training sets are derived through
use of the literature and other potentially biased infor-
mation sources. However, OPEN frees itself completely
from investigation bias in its use of unbiased genomic
features to assess similarity among genes and thereby
exploit these refined positive training examples to make
new predictions.
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In principle, any gene feature expected to be held (or
avoided) in concert for disease genes can be used in this
approach. However, given our concern for biasing predic-
tions towards well-studied genes, we built an extensive set
of >40,000 features with minimal preference for previously
characterized genes. Genomic features were derived from
publicly available genome-wide expression data, trans-
cription factor binding information (both observed and
predicted), phylogenetic profiles, protein domain orga-
nization, and predicted microRNA (miRNA) targets
(Table 1). In most cases, preprocessing was required to
generate useful predictors. For example, for microarray
analysis, we automated downloading, normalization, clus-
tering, and differential gene expression analysis for 1,437
human and murine microarray data sets obtained through
the Gene Expression Omnibus (GEO) [23]. As a compari-
son to assess the impact of biased features on our predic-
tions, we also downloaded GO annotations and used each
of the 17,156 terms as descriptive features.
Principled prioritization
A recurring message in the interpretation of GWA data
for many traits is that, for a (sometimes small) subset of
Figure 1 A decision tree-based approach for causal gene prediction. (A) Mapping of SNPs to neighboring genes using a combination of
linkage disequilibrium (LD) information and the location of recombination hotspots. (B) Workflow applying OPEN for causal gene prediction at
GWA loci. GWA loci are represented by horizontal bars with individual genes represented by vertical bars. The bar height represents the probability
that a gene is causal for the phenotype of interest. Initially, all probabilities are equal. Probabilities are then preliminarily updated based on physical
distance from index variant or, optionally, if any prior experimental evidence links them to the phenotype of interest. These probabilities are used in
the sampling of positive training examples at each locus during the construction of decision trees. After a 'burn-in' phase, only genes meeting a
probability threshold are used as positive training examples. Through cross-validation, the output of the analysis is the log-odds of disease association
for all genes in the genome. GBM, gradient boosting machine. (C) Representation of a sample decision tree used for partitioning positive and negative
training examples. A classifier consists of multiple decision trees combined in an additive manner.
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prior experimental work. Such evidence might include
linkage studies of a corresponding Mendelian disease or
might have emerged from the thousands of mouse genetic
models previously generated. In the case of lipid profiles,
for example, 16 of 21 genes involved in Mendelian forms
of cholesterol or triglyceride disorders (Additional file 1)
also harbor common variants significantly associated with
cholesterol/triglyceride levels in GWA studies. Similarly,
at least 10% of loci implicated in height contain at least
one gene that had been previously implicated in skeletal
morphology [7]. We sought to apply this information sys-
tematically as a source for weighting individual gene can-
didates within GWA loci, upweighting specific training
examples that were also causally mutated for a corre-
sponding Mendelian disease or that share GO or mouse
phenotype annotation with genes from other associated
loci (Materials and methods; Additional file 2). We also
used a more stringently defined set of these upweighted
training examples as 'likely positives' for performance met-
rics (see below).
An adaptation of the gradient boosting algorithm for
analyzing genetic loci
In principle, the OPEN approach is compatible with a
number of machine learning algorithms. We selected
and adapted the gradient boosting machine (GBM) algo-
rithm [24], in part because of its suitability for learning
problems where only a small fraction of features exam-
ined are informative [25], and because of the ability to
perform stochastic sampling of training examples, which
is well suited to the problem of finding the most likely
gene(s) explaining the association signal at GWA loci.
GBM, which was a critical component of the winning
'Netflix Grand Prize' solution [26,27], has been used
for a variety of biological and medical machine learn-
ing problems, including deciphering the tissue-specific
splicing code [28] and predicting clinical outcomes in
osteoporosis [29]. GBM builds an additive expansion
of small decision trees (Figure 1B), with each tree par-
titioning genes based on a series of informative features
differentiating positive and negative training examples.
Boosting is used so that successive decision trees focus on
classifying those examples that had been poorly differen-
tiated up to that point. Stochasticity is introduced by
subsampling positive and negative training examples for
each tree.
Machine learning using positive training examples
from GWA loci presents a particular problem because
of the organization of genes in the genome - specifically
the fact that genome often harbors clusters of contiguous
functionally related paralogs. Extreme examples include
the olfactory gene cluster at the 11p15.4 region, the his-
tone cluster at 6p22.1, and the interleukin receptor cluster
at 2q12. If one naively put all genes at all associated loci in
a 'bag' and looked for shared features, one could identify a
feature common to dozens of paralogous genes within
one locus that is not shared by genes within any other
locus. Under the assumption that one or perhaps only a
few genes underlie the GWA signal at any locus, it is
essential to find features shared across loci rather than
within loci. Our stochastic sampling scheme thus sampled
only a single gene at each locus, with probability of
sampling given by its weight.
Performance evaluation
Cross-validation was used to estimate the odds of disease
association for every gene in the genome. We initially
Table 1 Genomic features used in OPEN
Data type Data source Number of features
Differential mRNA expression GEO - human 15,778
Differential mRNA expression GEO - mouse 4,780
Tissue mRNA expression - percentile Novartis Tissue Atlas 158
Tissue mRNA expression - percentile Neurocrine Tissue Atlas 2,031
Tissue mRNA expression - comparison Neurocrine Tissue Atlas 141
mRNA expression clusters Liver 148
mRNA expression clusters Multi-tissue 108
Protein domain organization Interpro 12,624
Predicted conserved TFBS Vista 2,336
Chip-Seq Encode/GEO 2,073
Predicted TFBS PWM (Jasper/Transfac/Uniprobe) 12,624
Predicted conserved TFBS Vista 2,336
miRNA predicted binding sites TargetScan 153
Phylogenetic profiles Ensembl 49
GEO, Gene Expression Omnibus; PWM, position weight matrix; TFBS, transcription factor binding site.
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GWA studies had identified 10 or more significantly
associated loci (Figure 2A-D). These included plasma
concentrations of cholesterol subfractions (high-density
lipoprotein-cholesterol (HDL-C), low-density lipoprotein
(LDL)-cholesterol, total cholesterol), plasma triglycerides,
hypertension/blood pressure, heart rate, and three elec-
trocardiographic phenotypes (QRS duration, QT interval,
PR interval, as well as pooled phenotypes of all of these).
The primary use of our causal gene prioritization is for
the correct ordering of a short list of genes, either within
a locus found through a GWA study or obtained through
filter-based variant prioritization for gene sequencing
studies. We therefore evaluated the results in three ways
compatible with these goals. First we used the area under
the receiver operating characteristic curve (AUROC),
which assesses the probability of successfully discrimi-
nating a randomly chosen positive training example from
a random negative example. Second, we used a permuta-
tion-based assessment of the chance that 'likely positives'
would rank near the top of the list of genes at each disease
locus (Materials and methods). This metric most closely
coincides with the needs of biologists pursuing GWA
signals, pedigree-based linkage peaks or filtered lists of
exome sequencing variants, where the goal is to identify
the most likely candidate among a limited subset of genes.
Finally, we used precision (fraction of predictions that are
correct, also known as positive predictive value) at specific
levels of sensitivity to assess whether an experimentalist
who did not have access to genetic data and instead pro-
ceeded down the list of predictions validating each one by
one would find a high percentage of successes.
Focusing on serum LDL-cholesterol as a phenotype,
cross-validation showed an AUROC of 0.91, indicating
excellent performance (an AUROC of 1 represents per-
fect classification, while a value of 0.5 is no better than
random chance; Figure 2A). Moreover, we were able to
prioritize 28 of the 38 total 'likely positive' genes at or
near the top of their respective loci (P<0.0001, Fisher?s
exact test; Figure 2B,C). For example, at the 5q13.3 locus
we prioritized the statin target HMGCR as the most
likely causal gene, despite only using unbiased genomic
features as predictors. Similarly, at the 2p15 locus, we
prioritized EHBP1, which was recently shown to be
associated with the Mendelian LDL-cholesterol gene
and therapeutic target PCSK9 in murine and cellular
models [30]. Overall, performance figures for other car-
diac phenotypes were also excellent, with AUROC values
ranging between 0.75 and 0.9 (Additional file 3). Repeating
the analysis of cardiac phenotypes without the use of prior
information to up-weight training genes resulted in only a
moderate drop in performance (for example, from 0.85
to 0.80 for triglycerides, from 0.84 to 0.78 for cardiac
conduction phenotypes). This suggests that while prior
evidence is certainly an asset for prediction, it does not
appear to be a requirement.
Performance estimates based on genome-wide preci-
sion or positive predictive value of highly ranked genes
were not as strong as AUROC results for classification
within implicated loci (Additional file 3). The precision
(positive predictive value) at 20% recall (sensitivity) ranged
from 2 to 6% for lipid profile traits, and lower for other
traits. While 2 to 6% precision is far better than would
have been expected by chance (for example 0.1% is ex-
pected for plasma triglycerides, P=6. 6?10
-5), whether it
is sufficient to justify sequential experimental validation of
targets depends on the value of identifying new causal
genes relative to the expense of the experimental validation
effort. Investigators may also have additional orthogonal
evidence that might be used to further enrich posi-
tives within this prioritized list, allowing a pinpointing
of causal genes.
Applying OPEN to non-cardiac traits
Given the breadth of our genomic features, OPEN should
be also effective in pinpointing causal genes across non-
cardiac phenotypes. We therefore extended our approach
to 26 additional non-cardiac traits, including autoimmune,
hematologic, metabolic and cancer phenotypes, and
observed strong success in prioritizing causal genes
(Additional files 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,
15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,
29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 and 41).
For example, we successfully prioritize 27 of 35 likely
positives involved in type 2 diabetes and glucose pheno-
types (P<0.0001) with an AUROC of 0.83. Thus, OPEN
generalizes well to non-cardiac traits.
Applying OPEN to the heritable cardiomyopathies
In addition to complex types of CVD, there exist a
number of monogenic forms, which, in aggregate, are
significant contributors to cardiovascular morbidity and
mortality. The most prevalent form of monogenic CVD
are the cardiomyopathies (CMPs), which are debilitating,
frequently fatal diseases of the heart muscle, with a strong
heritable component [31]. CMPs have historically been
classified on the basis of anatomic and physiologic cha-
racteristics as belonging to hypertrophic (HCM), dilated
(DCM) or restrictive subtypes. Genetic linkage studies
have identified a number of disease genes underlying
HCM and DCM. Given that the first presentation of CMP
can be sudden cardiac death, knowledge of such genes
has been of considerable value in clinical care, as it
allows genetic screening of family members, resulting
in careful surveillance of mutation-carrying but asymp-
tomatic individuals and early implantation of life-saving
defibrillator therapy.
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HCM can be explained by our current census of CMP
genes [32,33], genetic studies of CMP patients remain a
priority. Unfortunately, GWA results have been difficult
to interpret, as causal genes are hard to differentiate
amongst the many genes harboring rare mutations [34].
To provide an unbiased, independent method of prio-
ritizing causal CMP genes, we applied our OPEN ap-
proach to HCM and DCM, using established causal
genes as training examples. OPEN successfully predicted
established CMP genes, as evidenced by an AUROC
of 0.88 and 0.96 for DCM and HCM, respectively
(Figure 3A). The prominent clustering of known CMP
causal genes at the top of the list (Figure 3B; precision at
20% recall of 19% for DCM and 42% for HCM) strongly
suggests that OPEN scores could be integrated with
sequencing data to choose candidates for experimen-
tal validation.
Interpreting GWA study data using Mendelian disease
predictions
We hypothesized that OPEN scores for Mendelian diseases
such as the CMPs could also be useful for interpreting
GWA study results for related phenotypes. For example, a
GWA study of DCM identified two loci at genome-wide
significance [22]. Overlaying OPEN DCM scores for each
of the genes at these loci revealed two promising candi-
dates (Figure 3C): BAG3, a recently identified causal DCM
gene [35], and HSBP7, a gene recently implicated in
protection against tachycardia-induced CMP [36] and
that also caused a reduction in cardiac output upon dis-
ruption in zebrafish [11].
Left ventricular diameter (LVD) is a heritable complex
trait that predicts incident congestive heart failure
and mortality [37]. A recent GWA meta-analysis of LVD
found only a single locus at genome-wide significance
[21], though interestingly, the locus includes PLN (which
encodes phospholamban), a known DCM gene [38]. Given
the phenotypic similarity between DCM and enlarged
LVD, we hypothesized that OPEN scores for DCM would
be useful to prioritize genes at LVD loci, even if these
failed to meet genome-wide significance in GWA analysis.
We first selected all SNPs with a nominal P-value of
5?10
-5 (considerably less stringent than the conven-
tionally accepted threshold of 5 ?10
-8 for significance),
mapped these to neighboring genes, and looked for
any loci where the top-ranked gene (according to
DCM score) had a higher score than that expected
based on random chance (see Materials and methods).
We found 11 such loci (of which 10 were multigenic;
Figure 4). For four of these loci, the top gene accord-
ing to OPEN had been shown to be mutated in DCM
(PLN, ACTN2, TNNT2, TTN) [39], while for two
others, the top gene was known to be mutated in
HCM (MYL2) or an arrhythmogenic form of cardiac
disease (CASQ2) [40]. For two more, the top gene
(GBE1 and APOBEC2) affects heart contractile func-
tion in animal models [41,42]. Note that the OPEN
procedure is ?clean?, in the sense that the score for any
given gene is derived from models that never used
that gene in training. Overall, the 'insignificant' LVD
GWA loci were highly enriched for genes causing
inherited abnormalities of the heart muscle (P =8?
10
-5, odds ratio=7.65, Fisher?s exact test).
Validating prioritized candidates in zebrafish
We focused on the remaining candidates (USP13,
FLNC, SVIL), which, at the time of our study, had no
known link to cardiac function but were attractive given
that: 1) they were found in loci that had been associated
with LVD; and 2) they had high OPEN scores for DCM
despite having a small number of genes at their locus.
All three ranked highly on our overall genome-wide
ranking of DCM candidates with FLNC being the num-
ber 2 candidate overall, USP13 number 105, and SVIL
number 298. We knocked each of these down in embry-
onic zebrafish and looked for evidence of phenotypic
change. All three demonstrated abnormalities in cardiac
morphology or function (Figure 5). Specifically, micro-
injection of a morpholino targeting USP13 caused a
dose-dependent decrease in cardiac output. Notably,
this decrease was due to both decreased ventricular
stroke volume and heart rate (Figure 5A). Next,
although previous efforts have described skeletal
muscle-specific defects following morpholino-based
introduction of a premature stop codon in flncb (one of
(See figure on previous page.)
Figure 2 OPEN successfully prioritizes causal genes for complex traits. (A) Receiver operating characteristic (ROC) curves for prioritization of
'likely positive' genes for LDL-cholesterol. (B) OPEN effectively prioritizes likely positives for low-density lipoprotein (LDL)-cholesterol within GWA
loci. A histogram shows the distribution of the number of genes prioritized by random chance over 10,000 independent simulations, with arrow
indicating the number prioritized by OPEN (P<0.0001). (C) OPEN successfully prioritizes the statin target HMGCR at the 5q13.3 locus (left). A
heatmap depicts the six genes at the LDL-associated 5q13.3 locus, with the first four columns indicating which genes are near the index variant,
and which have been annotated with prior evidence via the Gene Ontology (GO), Mouse Phenotype Database (MPD) or through the Online
Mendelian Inheritance in Man (OMIM) database. The final column depicts the OPEN score, with color scheme from beige to dark purple indicating
increasing magnitude of the log odds for disease association provided by OPEN. At the 2p15 LDL-associated locus (right), OPEN ranks the un-annotated
EHBP1 gene highest. (D) Area under the ROC curve (AUROC) values for cardiac (left) and non-cardiac phenotypes (right). EKG, electrocardiogram;
HDL, high-density lipoprotein.
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defects related to FLNC have not been explicitly de-
scribed. Following injection of a splice-blocking morpholino
we noted obvious distention of the atrium and backflow
upon cardiac contraction (Additional file 42). Immuno-
logical staining confirmed hypertrophy of atrial
Figure 3 OPEN successfully predicts cardiomyopathy genes. (A) ROC curves for hypertrophic cardiomyopathy (HCM, left) and dilated
cardiomyopathy (DCM, right). (B) Top ranked genes according to OPEN score for HCM. Log-odds of disease association are obtained through cross-validation.
Blue bars represent positive training examples. (C) OPEN scores for DCM (as a Mendelian disease) are useful for prioritizing genes at DCM GWA loci. Each
locus is represented by a scatter plot of OPEN score against chromosomal position, with every gene at the locus represented by a circle. Gene symbols
for top ranked genes are provided. Purple coloring indicates that BAG3 has already been implicated in a Mendelian form of DCM.
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showed a decrease in ventricular conduction velocity in
isolated hearts following flncb splice inhibition com-
pared with sham-injected controls, suggesting alterations
in junctional remodeling and cell-cell coupling (Figure 5B).
Finally, knockdown of our third candidate, SVIL,c a u s e d
obvious pericardial edema at low morpholino doses
(Figure 5C) with optical mapping confirming an under-
lying decrease in atrial conduction velocity.
To evaluate the extent to which incorporation of biased
features may compromise prioritization of previously un-
studied genes, we repeated the OPEN predictions for
DCM but included as predictive features >17,000 GO
categories. We noted that our experimentally validated
candidate USP13 dropped from 105 in our overall ranking
of genes in the genome down to 1,614 - which, depending
on the validation strategy and budget, would likely have
removed it from consideration for experimental follow-up.
Figure 4 OPEN scores for DCM successfully prioritize genes at loci identified through a GWA study for left ventricular diameter (LVD).
OPEN scores for DCM were mapped to genes at loci marginally associated with LVD (P<5?10
-5). Eleven loci have a high-scoring top-ranked gene
based on OPEN scores for DCM association. Blue coloring indicates the seven genes are mutated in Mendelian forms of cardiac disease, including
DCM, HCM, arrhythmogenic right ventricular cardiomyopathy and catecholaminergic polymorphic ventricular tachycardia (P=8?1 0
-5 for enrichment).
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exon sequencing in DCM patients
Given our experimental results, we hypothesized that
our prioritized list of DCM candidates may in fact help
identify disease-causing variants in actual patients. We
designed capture probes corresponding to all known
exons of established (34) and candidate (13) DCM genes
and genotyped 60 patients with idiopathic DCM using
next-generation sequencing at extremely high depth
(>700-fold). We focused on mutations with severe delete-
rious consequences, including nonsense, frame-shift, and
canonical splice acceptor/donor disruptions. In addition to
finding several truncating mutations in established DCM
genes (data not shown), we identified in one patient with
severe DCM (left ventricular ejection fraction of 25% and
incessant ventricular tachycardia) a novel splice acceptor
mutation in FLNC (c.3791 - 1 G>C) that is predicted to
lead to exclusion of a 53 amino acid exon and result in a
frame shift. For this patient, no established DCM genes
harbored predicted pathogenic mutations and a survey of
more than 7,500 control samples revealed no comparably
damaging mutations in FLNC (see Materials and methods).
C
B A
Figure 5 OPEN prioritized genes contribute to cardiac phenotypes in zebrafish. (A) Knockdown of USP13 caused a dose-dependent
decrease in cardiac output, due to both a decrease in heart rate and ventricular stroke volume. (B) Injection of a morpholino (MO) targeting a
specific splicing event in FLNCb (see Materials and methods) caused apparent cardiac-specific defects. Images on the right show embryos at
48 hours post-fertilization (hpf) with decreasing injected morpholino concentration. Optical mapping confirmed a significant decrease in cardiac
conduction velocity in isolated hearts following FLNCb splice inhibition (top right: isochronal maps on right, red box indicates measured region of
interest, isochrones are 5 ms apart). Conduction velocity was unaltered in other regions of the heart (middle right: bar graph, regions examined
were atrial inner curvature (AIC), atrial outer curvature (AOC), AV node (AV), ventricular inner curvature (VIC), and ventricular outer curvature
(VOC)). Additionally, FLNCb splice inhibition resulted in increased atrial cardiomyocyte size (bottom left: beta-catenin stained in green, DAPI in
blue, V and A denote ventricle and atria, respectively). RT-PCR confirmed inhibition of the predicted splicing event in FLNCb (bottom right). (C)
Knockdown of SVIL causes cardiac edema as well as noticeable spinal curvature at higher morhpolino doses, with only cardiac edema notable at
lower doses. Images on left again show decreasing morpholino dose at 48 hpf. Optical mapping (right) confirmed a significant decrease in atrial
conduction velocity following SVIL knockdown. ***P<0.001, **P< 0.01, *P< 0.05.
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of segregation at this time, this is, to our knowledge, the
first implication of an FLNC mutation in a CMP.
Discussion
Here we have demonstrated a novel approach (OPEN)
for unbiased disease-gene prioritization following genetic
screening. The OPEN approach is based on the use of
an informative collection of unbiased genomic features
coupled with a principled strategy towards incorporating
prior knowledge in the weighting of training examples.
OPEN provided demonstrably high quality predictions
for CMPs, but also had excellent performance across
multiple disease categories, suggesting that OPEN could
readily be expanded to any trait of interest. We then
demonstrated the practical utility of our approach through
prospective validation of candidate causal cardiovascular
disease genes in zebrafish and through genetic sequencing
of human cardiac disease patients.
With the discovery of a conserved splice site mutation
in FLNC in a patient with DCM, we propose a new
candidate for diagnostic testing of DCM patients. Since
fewer than 50% of DCM patients receive a positive result
from genetic testing [44], additional disease genes are of
particular value, as positive mutation information can
influence intensity of screening and implementation of
preventive therapies. Although FLNC had previously been
linked to myofibrillar myopathy [45], a disease of the skel-
etal muscle, it had not been implicated in cardiac disease.
Consistent with the behavior of such genes as BAG3, DES,
TTN,a n dCRYAB, FLNC appears to demonstrate plei-
otropy, with varying degrees of skeletal or cardiac manifes-
tations in individual patients.
Interestingly, despite several years of GWA studies, it
is still challenging to identify the most likely causal gene
within a locus, even after exhaustive experimental valid-
ation of multiple candidates [46]. At some loci, such as
the 1p36 hypertension locus, a large number of genes ap-
pear to play a causal role [47]. This multiplicity of causal
genes justifies our strategy of scoring all genes at a locus
rather than simply choosing one candidate as the most
likely.
While broadly applicable, the OPEN approach does
have some notable limitations. First, as in any learning
approach, there was generally poorer performance in
those cases where training information was sparse. How-
ever, even in some cases with an apparent abundance of
training information, such as was available for weight
phenotypes, performance was poor (AUROC 0.65). This
is analogous to what we have seen for phenotype predic-
tions in other organisms [11], as genetic heterogeneity of
a particular phenotype or trait can cause ambiguity in
the predictions, manifesting as poor performance.
Additionally, precision-recall rates were lower than
expected based on comparable AUROC results; however,
there are several potential explanations for this observa-
tion. First, there is the challenge of knowing the actual
true positive for performance evaluation. We have used
a deliberately simple heuristic approach to selecting a
'likely positive', but in many cases this may be incorrect,
and other genes we prioritize at a given locus may be
playing a more substantial causal role. Similarly, there
may be false negatives among those genes we have
ranked highly that have not (yet) been found within
disease-associated loci. Some of these may in fact play a
role in the disease process but lack a common variant that
regulates their expression substantially in the cohorts that
have been studied and thus are not likely to be discovered
through GWA. Additionally, our unbiased genomic fea-
tures may simply be too weak to identify relationships
among causal genes that differ widely in terms of patho-
genic mechanism. Consequently, as unbiased genome-
scale data continue to be generated in disease-relevant
mammalian models and cell culture lines, we expect the
accuracy of the OPEN approach to increase in turn.
Finally, at this time, we were not able to incorporate
expression quantitative trait loci information into our
scheme, in part because it is lacking at sufficient scale for
the majority of human tissues. Moreover, even with ad-
equate expression quantitative trait loci information, one
often fails to pinpoint a single causal gene and can still be
left with a list of genes for further prioritization. However,
this could in the future serve as one of many potentially
valuable orthogonal data types to refine predictions.
Conclusions
We have described a principled strategy for prioritizing
causal disease genes that demonstrates great success in
identifying causal genes for a number of CVD-related
traits. By virtue of its reliance on unbiased predictive
features, our approach should contribute to the discovery
of causal genes using the vast amounts of genetic data
emerging from genotyping and sequencing technologies.
As genetic data continue to emerge from SNP-array and
sequencing technologies, developing techniques capable
of quickly identifying underlying causal genes will be
essential for disease diagnosis and treatment.
Materials and methods
Adaptation of the gradient boosting machine algorithm
for OPEN
The GBM algorithm [24] uses an additive expansion
of decision trees to determine probabilities for objects
(genes in this case) belonging to classes (diseases) of
interest. The boosting aspect refers to the fact that
every successive tree in the expansion focuses on ac-
curately classifying those training examples predicted
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accuracy is incrementally improved with each successive
tree. Stochasticity is introduced by selecting a subset of
training examples for each tree. For every tree, at each
split point, features are selected to minimize a loss func-
tion (absolute loss, in this case) that reflects the difference
between the actual values of the training examples (1 for
positive training examples and 0 for negative training ex-
amples) and the predicted probabilities (between 0 and 1)
generated by the ensemble of decision trees to that point.
All features are considered for every tree; although this
substantially improves performance in situations where
the percentage of predictive features is very low, which we
expected to be the case for gene-disease predictions, it
requires other measures to prevent overfitting. For GBM,
overfitting is minimized by: 1) selecting only a subset of
training examples per tree; 2) the height of the trees per-
mitted (number of terminal leaves); 3) the weight added to
the log-odds output of each tree (a shrinkage parameter);
and 4) the number of trees in the expansion. We opti-
mized all parameters for disease class prediction.
We used six rounds of eight-fold cross-validation, and
for each round built an additive expansion of sixty small
trees, each with three split points (four terminal leaves).
Cross-validation involved holding out a fraction of loci
from GWA studies, or a fraction of genes for Mendelian
diseases. For each tree, stochasticity was introduced by
using genes from 70% of loci (or in the case of Mendelian
diseases, 70% of genes) to provide positive training exam-
ples. Matching numbers of negative training examples
were selected. After each tree was completed, we updated
the function relating predictive variables to disease class,
which could be transformed to provide a log-odds of
disease association for every gene.
For GWA-based prediction, we took a probabilistic
approach to selecting positive training examples for each
tree. Initially, all genes at a locus were assigned a null
probability of being the causal gene (represented by a
score of 0). We then increased the score by 5 for those
genes with a transcription start site within a certain
distance from the index variant (50 kb), based on the
reasoning that if this proves to be the causal variant, it is
more likely to influence expression of neighboring genes.
Quantitative models of transcription based on empirical
data have documented a substantial contribution of tran-
scription factor binding sites (TFBSs) influencing expres-
sion up to 50 kb from the transcription start site [48].
We also explored upweighting the initial score assigned
to positive training examples based on prior experimental
evidence of involvement in a similar disease or biological
process. The majority of prior GWA experiments have
demonstrated that multiple loci underlying complex traits
include genes already demonstrated to influence a com-
parable trait, either in model organisms, cell lines, or in
Mendelian forms of the disease. We sought to use this in-
formation for two purposes: reweighting positive training
examples, and performance assessment (see below).
For each complex trait studied, we consulted three
separate ontologies for related terms: the GO, the Mouse
Phenotype Database (MPD), and the Human Phenotype
Ontology Database (derived to characterize diseases
within the Online Mendelian Inheritance in Man (OMIM)
database). To identify GO terms enriched at GWA loci for
a given trait, we took the list of genes close to the index
variant and submitted these to the Funcassociate server
[49]. All GO terms with a multiple hypothesis testing
adjusted P-value of <0.05 and log odds score of >1 were
selected and all genes annotated to those terms and within
GWA loci increased in score by 5. We performed a similar
approach using phenotype-to-gene mappings derived
from MPD. In the small number of cases where no term
was significantly enriched at p-adj <0.05 and log odds
score >1, we relaxed one or both of these criteria if the
annotation and GWA trait appeared consistent from a
biological perspective.
Thus, for every gene within a GWA locus, we in-
creased its initial score by 5 for each form of evidence
that supported its implication in regulating the phenotype
of interest (we did not attempt to optimize the relative
weights contributed by each form of evidence). Thus, a
gene could have a maximum initial score of 20 (5 points
for proximity, and 5 points for implication by OMIM,
GO, and MPD) and a minimum score of 0. For loci where
there was only a single gene, this gene was given a score
of 1. The scores were converted to probabilities by as-
suming a total probability of 1 at each locus. Genes with
a score of 10 or higher were treated as 'likely positives'
(Additional file 2) to assess performance of OPEN
predictions.
For GWA-based prediction, a 'burn-in' set of 20 trees
was used to narrow the number of positive training ex-
amples towards a higher confidence set. At every locus,
each gene started off with a score between 0 and 20, and
a corresponding probability of being the causal gene. For
each tree, 70% of loci were selected, and at each locus, a
single positive training example was selected based on
this probability distribution for causality. Features were
selected to differentiate positive and negative training
examples, and the log-odds of disease association calcu-
lated for each positive training example. The score of the
gene at each locus with the highest OPEN-determined
log-odds of disease association was then increased by 1
and the process repeated. After 20 trees, the total score
for every locus was tallied, and only those genes with
scores >25% of this amount were kept as positive training
examples. The respective scores of these genes were then
fixed and used for probabilistic sampling for the subse-
quent 60 trees.
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require similar elaborate measures to narrow positive
training examples. Consequently, no 'burn-in' period was
used - and 60 trees were built for classification for each
of six rounds of eight-fold cross-validation.
Predictive genomic features used for OPEN
Expression microarray
Overview of microarray processing Microarray data were
analyzed using R/Bioconductor [50]. Raw data were ini-
tially normalized by robust multi-array averaging (RMA)
[51] using a custom Chip Description File (CDF) from
the Michigan Microarray Lab Version 13) [52]. The
Michigan Microarray Lab CDF reanalyzes and matches
each probe sequence to the most current gene anno-
tation and produces summarized expression values. Dif-
ferential gene expression was determined using limma
[53], with a Benjamini-Hochberg [54] adjustment ap-
plied for multiple hypothesis testing.
mRNA tissue expression Complete datasets correspon-
ding to the GNF Body Atlas [55] and Neurocrine Tissue
Atlases [56] were downloaded from GEO (GSE7307). The
GNF atlas includes 158 microarrays corresponding to 79
different human tissue types (2 technical replicates). The
Neurocrine atlas includes 676 microarrays corresponding
to 65 human tissue types or cell lines (normal and/or dis-
eased), from 10 donors (a total of 141 conditions were
available - such as 'normal prostate' or 'diseased prostate').
Intensities for the GNF arrays were averaged across re-
plicates. For each tissue atlas, the intensity corresponding
to the 75
th,9 0
th and 99
th percentile across all tissues was
identified. Only those probesets mapping uniquely to a
single gene were considered, and for those genes mapping
to multiple probesets, the probeset with the highest mean
expression across all tissues was used. Each combination
of percentile threshold and array was included as a single
feature, with 1s and 0s assigned to genes whose expression
exceeded or fell below the percentile cutoff, respectively.
Imputation was performed for any genes not included on
the microarrays.
Differential gene expression We hypothesized that
genes may have distinctive expression in specific tissues,
although not necessarily having high abundance. Thus,
for each of the 141 tissue or cell line expression datasets
mentioned in 2.1.2, we computed a list of genes that
were significantly over-expressed relative to all other tis-
sues (false discovery rate <0.05). Each gene list constituted
a single feature.
Gene signatures We devised an automated approach to
determine gene signatures for a large number of micro-
arrays experiments deposited in GEO. First we identified
all experiments performed on the two most commonly
used microarray platforms: Affymetrix Human Genome
U133A Plus 2.0 and Affymetrix Mouse Genome 430 2.0
Array. Next, for each experiment we downloaded all the
corresponding microarrays, normalized them, and per-
formed hierarchical clustering of samples using the hclust
function in the R statistical framework [57]. We defined
individual sample groups based on multiple cutpoints
along the dendrogram (corresponding to tree heights of
0.975, 0.95, 0.925) and evaluated differentially expressed
genes between groups using limma [53]. Features consisted
of genes that were significantly changed (false discovery
rate <0.15) for a given comparison. Separate features were
derived for up- and down-regulated genes. We were able
to derive features from 1,048 data series on the Affymetrix
Human Genome U133A Plus 2.0 platform, and from 389
d a t as e r i e so nt h eA f f y m e t r i xM o u s eG e n o m e4 3 02 . 0
Array platform.
Model-based clustering We performed model-based
clustering using the mclust package in R to identify genes
with correlated expression patterns [58]. Clustering was
performed on the Neurocrine tissue atlas (108 total clus-
ters), as well as on a dataset of 427 human liver samples
(GSE9588) [59]. Membership in each cluster was used as a
single binary feature.
Transcription factor binding sites
Evolutionarily conserved transcription factor binding
sites A list of predicted TFBSs based on evolutionary
conservation was downloaded from the ECRbase (Data-
base of Evolutionary Conserved Regions) website [60].
The exact file used was tfbs_ecrs.hg18mm9.v102.txt. In
this file, evolutionarily conserved sites were identified and
mapped to transcription factors in the TRANSFAC v9.4
database [61]. Chromosomal positions provided by
the authors were mapped to Refseq genes within
25 kb, and for each gene the number of each TFBS
was tallied. Four discrete features were created for
each TFBS, with a feature corresponding to whether a
g e n eh a d1 ,m o r et h a n1 ,m o r et h a n2 ,o rm o r et h a n
3 copies of the TFBS. Thus, a gene with five copies
of a given TFBS would have 1s for all the above fea-
tures while a gene with two copies would have a
score of 1, 1, 0 and 0 for the four features, respectively.
Since genes vary widely in the number of TFBSs, including
these four different features of varying stringency in-
creased the likelihood of having at least one informative
feature for every TFBS (that is, not predominantly 1s or 0s
for every gene).
Chip-Seq and ChIP-chip transcription factor binding
sites The results of 691 individual ChIP-chip or ChIP-Seq
experiments were downloaded from GEO [62] or the
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ive features. Each binding site was mapped to all nearby
genes (within 10 kb). Since genes could have one or more
nearby binding sites, we determined the number of binding
sites corresponding to the 75
th,9 0
th and 99
th percentile.
Each cutoff was used to derive a separate feature.
Predicted transcription factor binding sites Genome-
wide TFBSs were predicted for 809 position weight
matrices (PWMs). The matching of a PWM to a sequence
was determined using an entropy-weighted motif match
score (MMS) defined as:
MMS ? −
X
b
X
j
wj log2 f bj=pb
  
X
j
wj
The MMS involves comparing the observed frequency
fbj of base b at each position j in the PWM with the
background frequency of that base pb in the genome and
summing over the length of the motif. The weight wj at
each position in the PWM is a function of the informa-
tion content:
wj ? 2−
X
log2 f bj
  
The MMS thus upweights matches at positions
where there is less ambiguity as to which base is pre-
ferred. We found that this modification resulted in more
consistency between binding sites predicted by PWMs
generated by different motif finding programs and greater
agreement with those predicted using PWMs in publicly
available databases (TRANSFAC [61] and JASPAR [64]).
Thresholds for determining the score required for a
match were determined separately for each motif by
generating the empiric distribution of scores for DNAse
accessible regions across a range of tissues. These scores
were fit to a three-component mixture model using the
mclust package [58]. The three components were inter-
preted as representing 'high confidence', 'intermediate
confidence' and 'low confidence' binding, and the lowest
value for the 'high confidence' group used as a threshold
for binding. Binding sites were mapped to genes as
described for 'ChIP-Seq and ChIP-chip TFBSs'.
Protein domain composition
Protein domain compositions were extracted from the
file protein2ipr.dat downloaded from the Interpro web
site [65]. For each protein domain, we generated a single
feature corresponding to all proteins with one or more
domains of that type. A total of 12,623 protein domains
were included as features.
Predicted miRNA binding sites
Predicted target sites for 153 miRNAs were downloaded
from the TargetScan database [66], with targets for each
miRNA used as a single feature.
Phylogenetic profiles
Phylogenetic profiles, consisting of the presence or absence
of human gene orthologs in 49 other species, were down-
loaded from the Ensembl database [67]. Presence or ab-
sence of an ortholog in each species was used as a feature.
Phenotype-to-gene mapping
The 'Catalog of Published Genome-wide association
Studies' was downloaded from [68]. The catalog reports
the top SNPs from >200 GWA study publications, along
with P-values of association and a phenotype descrip-
tion. We mapped nearly all GWA study phenotypes to
an ontology of phenotype(s), based on the Human
Phenotype Ontology [69]. Phenotypes with insufficient
numbers of training examples were pooled into composite
phenotypes (Additional file 43). We selected a P-value
threshold of 5?10
-8, and mapped all SNPs that met this
criterion to the corresponding phenotype. Most pheno-
types included multiple SNPs, often from multiple GWA
study publications. We then mapped SNPs to genes,
broadly following a previously described strategy [14] with
some modifications. An interval was defined for each SNP
to include all SNPs in the HapMap [70] that were within
an r
2 of 0.5 of the tag SNP. Each interval was then ex-
tended out to the next recombination hotspot, which was
obtained from the SNP Recomb Hots Track in the UCSC
Genome Browser and mapped to hg18 using the liftover
tool. Given that enhancers can act at considerable dis-
tance, we then extended each locus outward an additional
250 kb. All genes whose transcription start site position
was included within the SNP interval were then mapped
to that SNP (and therefore to the corresponding pheno-
type). If no gene was found within the SNP interval, the
SNP interval was extended 50 kb upstream and down-
stream of the SNP position and the search for overlapping
genes repeated.
For HCM and DCM we started from several recent
reviews [39,71,72] of genes implicated through family
studies and updated these with any additional examples
from the literature and commercial genetic testing panels
that had not been considered (Additional file 44).
Performance assessment
ROC curves
Receiver operating characteristic (ROC) curves evaluate
the sensitivity and specificity of prioritizing true positives.
Although 'true positives' are clear for Mendelian disease
prediction, no such list exists for any GWA trait. Instead
we used the 'likely positive' gene set, which should not be
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gradient boosting machine algorithm for OPEN' section
above). The AUROC and precision-recall statistics were
determined using the ROCR R package and in-house
scripts [11]. Statistical significance of the observed pre-
cision at 20% recall was determined by assuming a bino-
mial distribution for the inclusion of 'likely positive' genes
within any given subset of genes.
Permutation approach to assess the significance of gene
rankings
Prioritization of 'likely positives'
We assessed the significance of prioritization of 'likely
positives' by using as our test statistic the number of
times a 'likely positive' candidate was found in the top
three ranked genes across all loci for a trait. For loci with
three genes, we counted the number of instances where
a likely positive gene was in the top two, and for loci
with two genes, we counted the number of instances of
ranking the likely positive gene the higher of the two. To
evaluate the significance of this result, we determined
the null distribution of the test statistic by permuting
the ranks of genes at each loci 10,000 times.
High scoring top-ranked genes at LVD loci
To evaluate the statistical significance of top ranked
scores at the LVD loci, for each locus mapping to n
genes, we generated the null distribution of scores by
randomly sampling n genes from the distribution of
scores 10,000 times, and recording the top score for
each iteration. The empirical P-value was computed by
identifying the fraction of iterations with top scores
equal to or greater than the observed score.
To compute the enrichment of cardiomyopathy genes
among LVD loci (478 genes; Additional file 45), we con-
structed a list of 48 genes causally mutated in CMPs
(Additional file 46) and performed Fisher?s exact test,
assuming a 'universe' of 21,626 genes. We found seven
genes at the intersection: ACTN2, MYL2, PLN, RYR2,
TMEM43, TNNT2, TTN. We did not consider CASQ2,
which is responsible for a primarily arrhythmogenic phe-
notype in humans, as a success, although it does result in
ventricular defects in animal mutants [40].
Experimental validation of LVD prediction in zebrafish
Zebrafish morpholino injection
ATG- and splice-blocking morpholinos were designed
using Gene Tools? oligo design service [73]. Resulting
morpholino sequences were aligned against the zebrafish
genome using BLAST [74] to ensure a lack of off-target
binding. Morpholinos were re-suspended in sterile water
to a concentration of 1 mM and diluted to working
concentration with Danieau?s solution (58 mM NaCl,
0.7 mM KCl, 0.4 mM MgSO4, 0.6 mM Ca(NO3)2,5m M
HEPES). Male and female wild-type adult zebrafish were
housed and embryos bred using standard protocols [75].
Morpholinos were introduced into the zebrafish yolk via
microinjection at no later than the two-cell developmental
stage. Injected embryos were then kept at 28.5?C in E3
solution (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2,
0.33 mM MgSO4).
Measurement of cardiac output
Videos at 250 fps of beating hearts were taken from live
48 hours post-fertilization (hpf) embryos using an Axioplan
(Zeiss) upright microscope with a 5? objective lens and a
FastCam-PCI high-speed digital camera (Photron USA).
In-house software (implemented in MATLAB [76]; avail-
able upon request) was used to determine heart rate from
sequential image files, while measurements of ventricular
long and short axis in both diastole and systole were ob-
tained manually for each video using ImageJ [77] and used
to estimate chamber volume using standard geometric as-
sumptions. Cardiac output was then calculated as diastolic
minus systolic ventricular volume multiplied by heart rate,
as previously described [11].
Voltage mapping
Hearts were isolated from embryos at 48 hpf and stained
with the transmembrane-potential-sensitive dye di-8-
ANEPPS (Life Technologies, Carlsbad, CA, USA). Resul-
ting fluorescence intensities were recorded with a high-
speed charge-coupled-device camera (RedShirtImaging,
Decatur, GA, USA) and images analyzed using software
implemented in MATLAB [76]. For all comparisons
regions of interest were determined and compared be-
tween morpholino injected embryos and controls from at
least two separate mate pairings using a two-sided
Student?s t-test.
Immunostaining
Hearts were isolated from embryos at 48 hpf and fixed
using Prefer fixative (Anatech, Battle Creek, MI, USA).
Fixed hearts were permeabilized using Phosphate Buffered
Saline with Tween 20 and incubated overnight with a
1:200 diluted mouse anti-beta-catenin primary antibody
(BD Biosciences, San Jose, CA, USA), then subsequently
incubated with a 1:1,000 diluted donkey anti-mouse Alexa
Fluor 488 conjugated secondary antibody (Life Technolo-
gies). Hearts were mounted using ProLong Gold Antifade
Reagent with DAPI (Life Technologies) and imaged using
a Leica SP5X laser scanning confocal microscope at
63? magnification. Resulting images were analyzed
using ImageJ.
Capture-based sequencing
NimbleGen?s SeqCap EZ Choice technology was used to
construct oligonucleotide probes complementary to all
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predicted to be involved in Mendelian forms of cardiac
disease (Additional file 47). To identify established
DCM candidates, we started from several recent reviews
[39,71,72] of genes identified through family studies and
updated these with any additional examples from the
literature and commercial genetic testing panels. We in-
cluded 13 additional candidates from our OPEN DCM
candidates, primarily guided by interests in proteostasis
and cardiac-specific splicing as well as three prioritized
candidates from the LVD GWAS (FLNC, USP13, SVIL).
Genomic DNA from 60 patients with idiopathic DCM
enrolled in the Heart Failure Clinic at the University of
California San Francisco was prepared using the Kapa
Biosystems Library Preparation Kit, hybridized to the
capture probes, and sequenced on an Illumina HiSeq 2000
sequencer. Multiplexing of 24 samples per lane of the se-
quencer flow cell yielded a median coverage of >700-fold,
with fewer than 30 base pairs per sample having less than
30-fold coverage. Assembly was performed using bwa
[78] and variants called using the GATK [79] (Additional
file 48). Sanger sequencing was used to validate the FLNC
splice site mutation. To assess the rate of FLNC mutations
in controls, Variant Call Format files for the NHLBI
Exome Sequencing Project [34] and 1000 Genomes Pro-
ject [80] (1000 Genomes Project Consortium, 2010) were
downloaded and annotated for functional consequence.
The NHLBI exome data included two rare out-of-frame
deletions (chr7:128498119 CTG>C and chr7:128498167
CCA>C) mapping to the carboxy-terminal 5% of the
protein, a location of enrichment for common indels
[81]. No similarly deleterious mutations were found in
the 1000 Genomes data. Informed consent precludes
re-contacting individuals for further study.
Ethics
Human genetic studies were performed according to in-
stitutional guidelines and with the full approval of the
University of California San Francisco Committee on
Human Research (CHR #H1083-33104 and #10-00207)
and all studies performed were in keeping with the ori-
ginal informed consent forms.
All zebrafish experimental work conforms to the ?Guide
for the Care and Use of Laboratory Animals? published by
the US National Institutes of Health (NIH Publication No.
85-23, revised 1996).
Data deposition
Source code is available for download under a Creative
Commons License at [82]. Sequencing data have been
deposited in the Sequence Read Archive (SRA) under
BioProject accession SRP049169.
OPEN predictions for GWA loci are available at
http://cvri.ucsf.edu/~deo/disease_mapping.html.
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Additional file 1: Table S1. The genes shared between Mendelian lipid
disorders and GWA loci for lipid traits.
Additional file 2: Table S2. Genes at the overlap of experimental
evidence and GWA loci.
Additional file 3: Table S3. OPEN performance metrics.
Additional file 4: Table S8. OPEN predictions for height.
Additional file 5: Table S9. OPEN predictions for rheumatoid arthritis.
Additional file 6: Table S10. OPEN predictions for electrocardiogram
phenotypes.
Additional file 7: Table S11. OPEN predictions for QT interval.
Additional file 8: Table S12. OPEN predictions for cardiac conduction
phenotypes.
Additional file 9: Table S13. OPEN predictions for platelet phenotypes.
Additional file 10: Table S14. OPEN predictions for white blood cell
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Additional file 11: Table S15. OPEN predictions for leukemia.
Additional file 12: Table S16. OPEN predictions for inflammatory
bowel disease.
Additional file 13: Table S17. OPEN predictions for asthma.
Additional file 14: Table S18. OPEN predictions for uric acid levels.
Additional file 15: Table S19. OPEN predictions for Alzheimer disease.
Additional file 16: Table S20. OPEN predictions for celiac disease.
Additional file 17: Table S21. OPEN predictions for cancer.
Additional file 18: Table S22. OPEN predictions for systemic lupus
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Additional file 19: Table S23. OPEN predictions for breast cancer.
Additional file 20: Table S24. OPEN predictions for colon cancer.
Additional file 21: Table S25. OPEN predictions for high-density
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Additional file 22: Table S26. OPEN predictions for psoriasis.
Additional file 23: Table S27. OPEN predictions for weight phenotypes.
Additional file 24: Table S28. OPEN predictions for bone density.
Additional file 25: Table S29. OPEN predictions for PR interval.
Additional file 26: Table S30. OPEN predictions for chronic
lymphocytic leukiemia.
Additional file 27: Table S31. OPEN predictions for coronary artery
disease.
Additional file 28: Table S32. OPEN predictions for total cholesterol.
Additional file 29: Table S33. OPEN predictions for type I diabetes
mellitus.
Additional file 30: Table S34. OPEN predictions for LDL-cholesterol.
Additional file 31: Table S35. OPEN predictions for blood pressure
phenotypes.
Additional file 32: Table S36. OPEN predictions for triglycerides.
Additional file 33: Table S37. OPEN predictions for multiple sclerosis.
Additional file 34: Table S38. OPEN predictions for QRS duration.
Additional file 35: Table S39. OPEN predictions for heart rate.
Additional file 36: Table S40. OPEN predictions for C-reactive protein.
Additional file 37: Table S41. OPEN predictions for glucose phenotypes.
Additional file 38: Table S42. OPEN predictions for RBC and iron
phenotypes.
Additional file 39: Table S43. OPEN predictions for kidney function.
Additional file 40: Table S44. OPEN predictions for primary biliary
cirrhosis.
Additional file 41: Table S45. OPEN predictions for fibrinogen.
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